Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study

Norwegian study (5,620 diagnoses of first testicular cancer [TC]) found that age at diagnosis influenced risk of second TC. For each additional cycle of cisplatin based chemotherapy, the second TC risk decreased after 3, 4 and >4 cycles (HRs 0.53, 0.41 and 0.21 respectively).

Journal of Clinical Oncology